Blood Cancer Journal · 2016 · 53 citations · 46 references
Life SciencesBioinformaticsImmunologyInflammationMolecular OncologyTranscriptomicsCytokine BiologyExpression Signature DiscoveryImmuno-oncology BiomarkersInflammatory BiomarkersInflammatory SignalingMultiple MyelomaBone Marrow InflammationDisease Progression PredictionImmune Gene Expression SignaturesInflammatory Response GenesMyeloma PathogenesisPrognostic Expression SignaturesPrognostic Gene SignaturesPrognostic Inflammatory Biomarkers
Multiple myeloma (MM) is closely dependent on cross-talk between malignant plasma cells and cellular components of the inflammatory/immunosuppressive bone marrow milieu, which promotes disease progression, drug resistance, neo-angiogenesis, bone destruction and immune-impairment. We investigated the relevance of inflammatory genes in predicting disease evolution and patient survival. A bioinformatics study by Ingenuity Pathway Analysis on gene expression profiling dataset of monoclonal gammopathy of undetermined significance, smoldering and symptomatic-MM, identified inflammatory and cytokine/chemokine pathways as the most progressively affected during disease evolution. We then selected 20 candidate genes involved in B-cell inflammation and we investigated their role in predicting clinical outcome, through univariate and multivariate analyses (log-rank test, logistic regression and Cox-regression model). We defined an 8-genes signature (IL8, IL10, IL17A, CCL3, CCL5, VEGFA, EBI3 and NOS2) identifying each condition (MGUS/smoldering/symptomatic-MM) with 84% accuracy. Moreover, six genes (IFNG, IL2, LTA, CCL2, VEGFA, CCL3) were found independently correlated with patients' survival. Patients whose MM cells expressed high levels of Th1 cytokines (IFNG/LTA/IL2/CCL2) and low levels of CCL3 and VEGFA, experienced the longest survival. On these six genes, we built a prognostic risk score that was validated in three additional independent datasets. In this study, we provide proof-of-concept that inflammation has a critical role in MM patient progression and survival. The inflammatory-gene prognostic signature validated in different datasets clearly indicates novel opportunities for personalized anti-MM treatment.
46
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Noëlia Casares, Marie O. Péquignot, Antoine Tesnière et al. · The Journal of Experimental Medicine · 2005 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron, Orianne Colussi, Elie Marcheteau et al. · The Journal of Experimental Medicine · 2015 · 1.2K citations · Full text
Medicine, Immunology, Oncology +17